Class Action Filed Against Atara Biotherapeutics Over Alleged Misstatements on FDA Setbacks

Overview

• - A class action has been filed in the U.S. District Court for the Central District of California, docket 26-cv-03083, on behalf of investors who bought Atara shares between May 20, 2024 and January 9, 2026.
• - Plaintiffs allege Atara misled investors by downplaying manufacturing lapses and weaknesses in the single‑arm ALLELE study, which they say made FDA approval of the tabelecleucel application unlikely.
• - The case cites FDA actions that hit the stock, including a January 2025 letter tied to problems found at a third‑party plant, a clinical hold days later over GMP compliance, and a January 12, 2026 letter rejecting the filing because ALLELE was not adequate and was confounded by its design, conduct, and analysis.
• - Investors seeking to lead the case must ask the court by May 22, 2026, as multiple firms including Pomerantz, Faruqi & Faruqi, Rosen Law Firm, and the Law Offices of Howard G. Smith recruit candidates.
• - Tabelecleucel is Atara’s lead therapy for EBV‑positive post‑transplant lymphoproliferative disease, and delays could strain funding and commercialization plans that depend on partner Pierre Fabre’s milestone payments.